腺素,利多卡因和Mg2+更新:教老药新技巧
Geoffrey P Dobson1, Jodie L Morris1, Hayley L Letson1
1Heart and Trauma Research Laboratory, College of Medicine and Dentistry, James Cook University, Townsville, QLD, Australia.
Frontiers in medicine
|October 13, 2023
概括
小量的腺,利多卡因和Mg2+ (ALM) 治疗改善了生存率,并减少了创伤患者的二次损伤. 这种创新的治疗方法在低血压复苏期间支持神经保护和心血管功能.
科学领域:
- 创伤和紧急医疗医学
- 药理学 药理学是指药理学的学科.
- 生理学 生理学 生理学
背景情况:
- 严重的创伤和感染可以压倒身体的恒温机制,导致高死亡率.
- 目前对严重出血性休克的治疗方法在改善结果方面存在局限性.
研究的目的:
- 审查小量腺,利多卡因和Mg2+ (ALM) 治疗在提高生存率和减轻二次损伤方面的疗效.
- 更新ALM治疗对非压缩性出血性休克,创伤和传染性状态的影响.
主要方法:
- 使用允许的低血压血压 (MAPs 50-60 mmHg) 进行复苏.
- 管理腺素,利多卡因和Mg2+ (ALM) 疗法.
- 对研究ALM对生理参数和临床结果的影响的研究分析.
主要成果:
- ALM疗法促进了血管扩张状态,维持了组织的氧气供应.
- 神经保护是在低血压时得到的.
- ALM改善心血管功能,降低炎症,纠正凝血病,恢复内皮糖体,并降低氧化应激.
结论:
- ALM疗法提供了一种有前途的方法,可以提高生存率,减少严重创伤和冲击状态中的二次损伤.
- 潜在的应用包括中风,肌肉创伤,REBOA辅助,烧伤多创伤,损伤控制手术和骨科手术.
- 在医院前和军事环境中探索临床实用性,特别是在非压缩性出血和创伤性脑损伤 (TBI) 中.
相关概念视频
Cardiopulmonary Resuscitation IV: Pharmacological Management
12
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
12
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
751
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
751
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
854
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
854
Heart Failure Drugs: Inotropic Agents
598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598


